Mostrar el registro sencillo del ítem
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
dc.contributor.author | Redondo, A. M. | |
dc.contributor.author | Valcárcel, D. | |
dc.contributor.author | González-Rodríguez, A. P. | |
dc.contributor.author | Suárez-Lledó, M. | |
dc.contributor.author | Bello López, José Luis | |
dc.contributor.author | Canales, M. | |
dc.contributor.author | Gayoso, J. | |
dc.contributor.author | Colorado, M. | |
dc.contributor.author | Jarque, I. | |
dc.contributor.author | del Campo, R. | |
dc.contributor.author | Arranz, R. | |
dc.contributor.author | Terol, M. J. | |
dc.contributor.author | Rifón, J. J. | |
dc.contributor.author | Rodríguez, M. J. | |
dc.contributor.author | Ramírez, M. J. | |
dc.contributor.author | Castro, N. | |
dc.contributor.author | Sánchez, A. | |
dc.contributor.author | López-Jiménez, J. | |
dc.contributor.author | Montes-Moreno, S. | |
dc.contributor.author | Briones, J. | |
dc.contributor.author | López, A. | |
dc.contributor.author | Palomera, L. | |
dc.contributor.author | López-Guillermo, A. | |
dc.contributor.author | Caballero, D. | |
dc.contributor.author | Martín, A. | |
dc.date.accessioned | 2021-11-30T11:12:51Z | |
dc.date.available | 2021-11-30T11:12:51Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/30548583 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/15783 | |
dc.description.abstract | We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3-year progression-free survival (PFS). Sixty patients (median age 55 [28-71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9-72) and 14 (4-53) days to achieve neutrophil and platelet counts of >0.5 x 10(9) /l and >20 x 10(9) /l, respectively. Non-relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow-up of 67 (40-77) months, the estimated 3-year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12-0.56]) and OS (RR, 0.40 [95% CI 0.17-0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies. | en |
dc.language.iso | eng | es |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Melphalan | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Podophyllotoxin | * |
dc.subject.mesh | Autografts | * |
dc.subject.mesh | Survival Rate | * |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | * |
dc.subject.mesh | Cytarabine | * |
dc.subject.mesh | Peripheral Blood Stem Cell Transplantation | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Disease-Free Survival | * |
dc.subject.mesh | Transplantation Conditioning | * |
dc.subject.mesh | Lymphoma | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Carmustine | * |
dc.title | Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group | en |
dc.type | Artigo | es |
dc.contributor.authorcorp | Grupo Español de Linfomas y Trasplante Autologo de Medula Osea | |
dc.authorsophos | Redondo, A. M. | |
dc.authorsophos | Valcárcel, D. | |
dc.authorsophos | González-Rodríguez, A. P. | |
dc.authorsophos | Suárez-Lledó, M. | |
dc.authorsophos | Bello, J. L. | |
dc.authorsophos | Canales, M. | |
dc.authorsophos | Gayoso, J. | |
dc.authorsophos | Colorado, M. | |
dc.authorsophos | Jarque, I. | |
dc.authorsophos | del Campo, R. | |
dc.authorsophos | Arranz, R. | |
dc.authorsophos | Terol, M. J. | |
dc.authorsophos | Rifón, J. J. | |
dc.authorsophos | Rodríguez, M. J. | |
dc.authorsophos | Ramírez, M. J. | |
dc.authorsophos | Castro, N. | |
dc.authorsophos | Sánchez, A. | |
dc.authorsophos | López-Jiménez, J. | |
dc.authorsophos | Montes-Moreno, S. | |
dc.authorsophos | Briones, J. | |
dc.authorsophos | López, A. | |
dc.authorsophos | Palomera, L. | |
dc.authorsophos | López-Guillermo, A. | |
dc.authorsophos | Caballero, D. | |
dc.authorsophos | Martín, A. | |
dc.authorsophos | the Grupo Espanol de Linfomas y Trasplante Autologo de Medula, Osea | |
dc.identifier.doi | 10.1111/bjh.15713 | |
dc.identifier.pmid | 30548583 | |
dc.identifier.sophos | 31823 | |
dc.issue.number | 5 | es |
dc.journal.title | BRITISH JOURNAL OF HAEMATOLOGY | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Hematoloxía clínica | es |
dc.page.initial | 797 | es |
dc.page.final | 807 | es |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.15713?download=true | es |
dc.rights.accessRights | embargoedAccess | es |
dc.subject.decs | linfoma | * |
dc.subject.decs | acondicionamiento para el trasplante | * |
dc.subject.decs | tasa de supervivencia | * |
dc.subject.decs | trasplante de células madre de sangre periférica | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | adulto | * |
dc.subject.decs | autoinjertos | * |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada | * |
dc.subject.decs | supervivencia sin enfermedad | * |
dc.subject.decs | anciano | * |
dc.subject.decs | melfalán | * |
dc.subject.decs | podofilotoxina | * |
dc.subject.decs | humanos | * |
dc.subject.decs | carmustina | * |
dc.subject.decs | citarabina | * |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 184 | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
![](/xmlui/themes/Mirage2//images/final_lines.png)